- Thinly traded nano cap Prana Biotechnology Ltd (PRAN +21.9%) is up on a healthy 32x surge in volume on the heels of its announcement that dosing is underway in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of Parkinson's disease (PD) candidate PBT434 in healthy volunteers.
- PBT434 belongs to a class of molecules called quinazolinones which block the accumulation and aggregation of a protein called alpha-synuclein which is associated with PD and Lewy body dementia.
Early-stage study commences for Prana's lead drug PBT434; shares ahead 22%
Recommended For You
About ATHE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ATHE | - | - |
Alterity Therapeutics Limited |